Key Decisions for Life Science Companies: Stay the Course or Exit via M&A?
By Andrew Levitch, Mark Murray, Patrick Nugent, Linda Rubinstein
This article is the fourth in a 4-part series reviewing financing solutions for the Life Science sector. Many life science companies are fortunate to reach a critical inflection point where leadership must face a decision: continue to fund growth to reach clinical milestones independently or exit via merger and acquisition….Read More
Read More5 Ways CFOs Can Lead Through Expert Negotiation
By Nancy Hargreaves
No longer confined to the back office, today’s CFOs are strategic partners who play a critical role in shaping the future of their organizations. As such, negotiation is one of the most crucial skills a CFO must master. CFOs negotiate high-stakes business objectives that can distinguish organizational success from failure….Read More
Read MoreIdentifying Red Flags: Signs Your Finance Function is Underperforming
By Anne Samak de la Cerda
At FLG Partners, our financial experts are often called into situations where the finance leader or finance team has been underperforming for some time, yet management has not taken timely action. These delays typically have significant repercussions, from missed opportunities to financial instability. Underperforming finance teams negatively impact the business…Read More
Read MoreCreative Financing Approaches in Life Science
By Andrew Levitch, Mark Murray, Patrick Nugent, Linda Rubinstein
This article is the third in a 4-part series reviewing financing solutions for the Life Science sector. As Life Science company valuations have fluctuated significantly over the last two years, and investors have become cautious due to economic turbulence and market uncertainty, fundraising is taking longer. Equity financing has been…Read More
Read More